Institute for Molecular Virology and McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, USA.
J Virol. 2023 Mar 30;97(3):e0002923. doi: 10.1128/jvi.00029-23. Epub 2023 Mar 1.
The major immediate early enhancer and promoter (MIEP) of human cytomegalovirus (HCMV) drives the transcription of the immediate early one (IE1) and IE2 genes, whose encoded proteins stimulate productive, lytic replication. The MIEP is activated by the virally encoded and tegument-delivered pp71 protein at the start of lytic infections of fully differentiated cells. Conversely, the MIEP is silenced at the start of latent infections within incompletely differentiated myeloid cells in part because tegument-delivered pp71 is sequestered in the cytoplasm in these cells, but also by viral factors that repress transcription from this locus, including the UL138 protein. During both modes of infection, MIEP activity can be increased by the histone deacetylase inhibitor valproic acid (VPA); however, UL138 inhibits the VPA-responsiveness of the MIEP. Here, we show that two families of cellular transcription factors, NF-κB and cAMP response element-binding protein (CREB), together control the VPA-mediated activation and UL138-mediated repression of the HCMV MIEP. Artificial regulation of the HCMV MIEP, either activation or repression, is an attractive potential means to target the latent reservoirs of virus for which there is currently no available intervention. The MIEP could be repressed to prevent latency reactivation or induced to drive the virus into the lytic stage that is visible to the immune system and inhibited by multiple small-molecule antiviral drugs. Understanding how the MIEP is regulated is a critical part of designing and implementing either strategy. Our revelation here that NF-κB and CREB control the responsiveness of the MIEP to the viral UL138 protein and the FDA-approved drug VPA could help in the formulation and execution of promoter regulatory strategies against latent HCMV.
人巨细胞病毒(HCMV)的主要早期增强子和启动子(MIEP)驱动早期基因 1(IE1)和 IE2 的转录,其编码的蛋白质刺激有活力的、裂解的复制。MIEP 在完全分化细胞的裂解感染开始时被病毒编码和被包膜递送到的 pp71 蛋白激活。相反,MIEP 在不完全分化的髓样细胞的潜伏感染开始时被沉默,部分原因是包膜递送到的 pp71 在这些细胞中被隔离在细胞质中,但也有病毒因素抑制从该基因座转录,包括 UL138 蛋白。在两种感染模式中,MIEP 活性可以通过组蛋白去乙酰化酶抑制剂丙戊酸(VPA)增加;然而,UL138 抑制 MIEP 对 VPA 的反应性。在这里,我们表明,两种细胞转录因子家族,NF-κB 和 cAMP 反应元件结合蛋白(CREB),共同控制 VPA 介导的 HCMV MIEP 的激活和 UL138 介导的抑制。人工调节 HCMV MIEP,无论是激活还是抑制,都是一种有吸引力的潜在方法,可以靶向目前尚无干预措施的病毒潜伏库。MIEP 可以被抑制以防止潜伏再激活,或被诱导进入裂解阶段,使免疫系统能够看到并被多种小分子抗病毒药物抑制。了解 MIEP 如何被调节是设计和实施这两种策略的关键部分。我们在这里揭示,NF-κB 和 CREB 控制 MIEP 对病毒 UL138 蛋白和美国食品和药物管理局批准的药物 VPA 的反应性,这可能有助于制定和执行针对潜伏 HCMV 的启动子调节策略。